Anthrasil Market Report 2026

Anthrasil Market Overview

• The Anthrasil market growth in the historic period has been driven by government biodefense initiatives, clinical success of immune globulin therapy • Market expansion is supported by continued public health preparedness funding, expansion of biodefense stockpiles • Growth Driver: Rising Anthrax Infections Drive Increased Focus On Anthrasil For Effective Treatment • Market Trend: Innovative Vaccine Solutions Boost The Anthrasil Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anthrasil Market?

Anthrasil is an anthrax immune globulin derived from the plasma of humans immunized with the anthrax vaccine, used in combination with antibiotics for the treatment of inhalational anthrax in both adults and children. It works by neutralizing anthrax toxins, thereby preventing cellular damage and mitigating the effects of the infection. The main types of anthrasil are 60U, and 100U. The 60U category includes anthrasil products packaged in 60-unit doses, designed for use in hospitals, clinics, and healthcare facilities. The Clinical indication types involved are inhalational anthrax, anthrax toxin neutralization, severe or systemic anthrax infections, prevention of disease progression in at-risk populations, and post-exposure prophylaxis (pep), The end users involved are hospital pharmacies, retail pharmacies, and others.

What Is The Anthrasil Market Growth Forecast?

The growth in the forecast period can be attributed to continued public health preparedness funding, expansion of biodefense stockpiles, rising focus on rapid toxin neutralization, improved plasma derived product processing, long term government purchasing agreements. Major trends in the forecast period include growing use of anthrax immune globulin therapies, expansion of combination treatment protocols, increased strategic stockpiling of immune globulins, rising focus on toxin neutralization therapies, enhanced pediatric and adult anthrax management.

Global Anthrasil Market Segmentation

1) By Type: 60U, 100U 2) By Clinical Indication: Inhalational Anthrax, Anthrax Toxin Neutralization, Severe or Systemic Anthrax Infections, Prevention of Disease Progression in At-Risk Populations, Post-Exposure Prophylaxis (PEP) 3) By End-User: Hospital Pharmacy, Retail Pharmacy, Other End-Users

What Is The Driver Of The Anthrasil Market?

An increasing prevalence of anthrax infections is expected to propel the growth of the anthrasil market going forward. Anthrax infections are caused by the bacterium Bacillus anthracis and can occur through skin contact, inhalation, or ingestion, leading to severe symptoms that vary based on the route of exposure. The rising prevalence of anthrax infections can be attributed to factors such as increased exposure to infected animals, inadequate veterinary supervision, and socio-economic challenges that hinder effective disease management and prevention. The growing incidence of anthrax infections results in more frequent use of anthrasil, as additional cases necessitate effective treatments to provide immediate passive immunity and improve survival rates. For instance, in December 2023, according to report published by World Health Organization (WHO), a Switzerland-based health authority, suspected anthrax cases in Zambia rose from 42 between September 2022 and January 2023 to 684 by November 20, 2023, including four deaths (0.6% CFR), across 44 districts in nine of the country's ten provinces. Therefore, increasing prevalence of anthrax infections is driving the anthrasil industry.

Key Players In The Global Anthrasil Market

Major companies operating in the anthrasil market are Emergent BioSolutions Inc.

Global Anthrasil Market Trends and Insights

Major companies operating in the anthrasil market are focusing on innovative vaccine development processes such as cell-free filtrate technology to enhance efficacy, improve safety profiles, and meet emerging bioterrorism threats. Cell-free filtrate technology uses non-living components from an avirulent strain of Bacillus anthracis to reduce the risk of adverse reactions while still effectively stimulating the immune system. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company that focuses on developing vaccines and antibody therapeutics for infectious diseases, received U.S. Food and Drug Administration (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), which represents a significant advancement in anthrax vaccination efforts. CYFENDUS incorporates an adjuvant known as CPG7909, which enhances the immune response, potentially leading to more robust and rapid antibody production against Bacillus anthracis. The vaccine is made from cell-free filtrates of an avirulent strain of B. anthracis, ensuring that it contains no live or dead bacteria, which may reduce the risk of adverse reactions compared to traditional vaccines that contain whole organisms.

What Are Latest Mergers And Acquisitions In The Anthrasil Market?

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired US sterile manufacturing facility from Emergent BioSolutions for an undisclosed amount. This acquisition allows Bora Pharma to expand its capabilities in the biotechnology and pharmaceutical sectors, strengthening its contract development and manufacturing services (CDMO) portfolio. Emergent BioSolutions Inc. is a US-based company that manufactures the anthrasil drug.

Regional Insights

North America was the largest region in the Anthrasil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Anthrasil Market?

The anthrasil market consists of sales of anthrasil (anthrax immune globulin intravenous - AIGIV), and anthrax vaccine adsorbed (AVA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anthrasil Market Report 2026?

The anthrasil market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anthrasil industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.